GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>…some aglycosylated proteins (proteins that are normally glycosylated but manufactured in a non-glycosylated form) sometimes have a tendency to be more labile to proteolysis, aggregation, and immunogenicity.<

1. GTC’s drug candidates can turn out differently glycosylated from their endogenous counterparts, but they are not aglycosylated.

2. In several clinical trials dating to the 1990s, ATryn has shown no immunogenicity in a large pool of human recipients. You may be barking up the wrong tree here.